Chronic wounds are a silent, growing epidemic, afflicting millions worldwide with sores that stubbornly refuse to heal for months or even years. Beneath their deceptively static surface lies a turbulent biochemical war zone where oxygen-starved tissues, relentless bacterial biofilms, and a hyperactive yet ineffective immune system conspire to derail the normal repair process. For decades, scientists have struggled to untangle this complexity using flat petri dishes and animal models that bear little resemblance to the inflamed, ischemic environment of a human diabetic foot ulcer. Now, a sweeping new review published in Nature Communications argues that the next revolution in wound care will not come from a magic bullet drug, but from a new generation of laboratory-engineered mini-tissues that finally capture the disease’s full, chaotic complexity.
The core challenge, as Argandoña and colleagues map out, is that a chronic wound is not simply an acute wound that stalled. It is a distinct pathological ecosystem. Standard cell cultures, where a single fibroblast type clings to a plastic surface, fail to replicate the mechanical stiffness of the wound bed, the low oxygen tension, or the continuous influx of inflammatory signals. Animal models, particularly the widely used diabetic mouse, heal wounds primarily through rapid skin contraction—a mechanism largely irrelevant to humans, whose wounds close via the slow migration of new tissue. This fundamental mismatch has caused countless therapies that looked miraculous in rodents to fail catastrophically in clinical trials, wasting billions and leaving patients without solutions. The paper systematically dismantles these inadequacies, making a compelling case that the field must pivot toward biofabricated human models that integrate living cells with precisely engineered microenvironments.
At the vanguard of this shift are organ-on-a-chip platforms and three-dimensional bioprinted constructs that read like science fiction turned reality. These devices use microfluidic channels narrower than a human hair to deliver nutrients and oxygen at precisely controlled gradients, mimicking the vascular insufficiency at the heart of chronicity. Within a single transparent chip, researchers can now co-culture keratinocytes struggling to migrate, dermal fibroblasts showing the senescent behavior typical of non-healing wounds, and immune cells like macrophages locked into a perpetual pro-inflammatory state. The review highlights how these systems can be placed under a microscope for real-time, days-long observation, revealing cellular cross-talk that remains invisible in animal studies. One of the most technically stunning advances is the ability to grow clinically-relevant bacterial biofilms directly onto these three-dimensional skin equivalents. Using methicillin-resistant Staphylococcus aureus isolated from actual patient wounds, the models recreate the vicious cycle of infection, where the host’s own immune cells degrade the tissue matrix in a futile attempt to clear bacteria, thereby feeding wound chronicity.
The technical sophistication extends deep into the material science underpinning these models. Argandoña and her co-authors illuminate how clever scaffold design can simulate the physical microenvironment of a chronic wound. Unlike the soft, pliable scaffolds used in traditional tissue engineering, chronic wound models require substrates with aberrantly high stiffness that replicate fibrotic dermis, driving cells to behave pathologically. Increasingly, these scaffolds are being rendered electrically conductive to allow for the integration of bioelectronic stimulation and monitoring. The review describes hydrogels infused with self-assembling peptides and tuneable growth factor delivery systems that can mimic the biochemical dysfunction of the wound exudate, a bitter soup of degraded proteins and corrosive enzymes that erodes healthy tissue. Some models now even incorporate a perfusable, leaky endothelial barrier to simulate the microvascular dysfunction of peripheral artery disease, allowing scientists to study why healing cells fail to reach the wound center.
Perhaps the most urgent application of these high-fidelity models is in the war against antimicrobial resistance. Chronic wounds serve as evolutionary incubators for drug-resistant pathogens, yet developing new antibiotics is notoriously slow. The paper details how microfluidic infection-on-a-chip platforms are accelerating this fight by enabling high-content screening of novel antimicrobial peptides and light-activated therapies. By loading these systems with patient-derived immune cells, researchers can observe not just whether a compound kills the bug, but whether it does so without triggering a destructive cytokine storm. This ability to interrogate the host-pathogen interface with molecular precision in a human-relevant context offers a radical new route to therapies that are both effective and gentle on struggling tissue.
Looking ahead, the vision laid out in this comprehensive roadmap is one of personalized wound medicine. The authors foresee a near future in which a small biopsy from a patient’s non-healing ulcer is used to populate a microfluidic chip seeded with their own cells, immune components, and the specific microbial strains colonizing their wound. Clinicians could then test a panel of tailored interventions—from smart dressings that release antibiotics only in the presence of bacterial toxins, to electrical stimulation protocols—to identify the optimal treatment for that individual’s unique biology before a single dressing is changed in the clinic. While formidable hurdles in standardizing these complex systems and securing regulatory approval remain, the engineering principles are solidifying rapidly. The once unimaginable goal of a synthetic human wound on a benchtop, a surrogate that bleeds, inflames, and in some cases finally heals under our watch, is no longer a distant prospect but a tangible piece of the modern biomedical arsenal.
Subject of Research: Engineering in vitro models to replicate the complexity of chronic wounds.
Article Title: Engineering in vitro models to replicate the complexity of chronic wounds.
Article References: Argandoña, L., Ivanova, K. & Tzanov, T. Engineering in vitro models to replicate the complexity of chronic wounds. Nat Commun (2026). https://doi.org/10.1038/s41467-026-75311-2
Image Credits: AI Generated
DOI: 10.1038/s41467-026-75311-2
Keywords: chronic wounds, in vitro models, organ-on-a-chip, biofilm, microfluidics, wound healing, tissue engineering, personalized medicine, antimicrobial resistance, host-pathogen interaction
